proteins, including pro-inflammatory cytokines that drive respiratory disease progression. Due 3 to its nature as an immediate-early gene (Carballo et al., 1998) and critical anti-inflammatory 4 molecule, it is not surprising that the expression and function of TTP is highly regulated and 5 amenable to rapid control in a mechanism akin to an on-off molecular switch. Critically, its 6 function is controlled by p38 MAPK: its mRNA expression is p38 MAPK-dependent (Mahtani 7 et al., 2001) ; and its mRNA destabilizing activity is controlled by p38 MAPK/MK2-mediated 8 phosphorylation on two key serine residues (S52 and S178) preventing initiation of mRNA 9 decay (Marchese et al., 2010) . 10
We were interested in understanding the molecular mechanisms responsible for TTP regulation 11 in order to develop strategies to enhance the anti-inflammatory capacity of TTP. Given the 12 critical role of p38 MAPK in TTP regulation, it might seem logical to attempt to block the p38 13 MAPK pathway to enhance TTP anti-inflammatory function. However, this approach has been 14 shown to be unsuccessful because it prevents expression of TTP mRNA in the first place, as 15 transcription of TTP is p38-MAPK dependent (Mahtani et al., 2001) . We suggest that a better 16 approach is to gain an in depth understanding of the temporal regulation of TTP expression and 17 control of its anti-inflammatory activity by p38 MAPK. Understanding cytokine regulatory 18 networks in this way will allow future development of novel pharmacotherapeutic approaches 19 that repress pro-inflammatory cytokines while ensuring that vital, anti-inflammatory proteins 20 necessary for disease resolution remain operational (reviewed in ). 21
Harnessing the power of the endogenous MAPK deactivator -mitogen-activated protein kinase 22 phosphatase 1 (MKP-1) -is one such approach. The phosphatase MKP-1 dephosphorylates 23 p38 MAPK (Manetsch et al., 2012a; Quante et al., 2008) and we recently demonstrated that the 24 precise temporal regulation of p38 MAPK phosphorylation status by MKP-1 ensured that TTP 25
Material and Methods 1

ASM cell culture 2
Human bronchi were obtained from patients undergoing surgical resection for carcinoma or 3 lung transplant donors in accordance with procedures approved by the Sydney South West 4
Area Health Service and the Human Research Ethics Committee of the University of Sydney. 5 ASM cells were dissected, purified and cultured as previously described by Johnson et al. 6 (Johnson et al., 1995) . A minimum of three different ASM primary cell lines were used for 7 each experiment. 8 9 Chemicals 10 TNF was purchased from R&D Systems (Minneapolis, MN). Unless otherwise specified, all 11 other chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO). 12 13
Real-time RT-PCR 14
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Doncaster, VIC, Australia) and 15 reverse transcribed using the RevertAid First strand cDNA Synthesis Kit (Fermentas Life  16 Sciences, Hanover, MD). Real-time RT-PCR was performed on an ABI Prism 7500 with IL-6 17 (Hs00174131_m1), TTP (Zfp36: Hs001856583_m1) and MKP-1 (DUSP1: Hs00610256_g1) 18 
Results
1
Temporal kinetics of TNF-induced IL-6 mRNA expression and protein secretion: impact 2 of treating with dexamethasone 1 hr after TNF stimulation 3
We (Ammit et al., 2002; Quante et al., 2008) there is no induction of IL-6 mRNA and adding dexamethasone in the absence of TNF (dex at 12 1 hr) had no effect on IL-6 mRNA expression. In accordance with our previous publications 13 Quante et al., 2008) Dexamethasone induces MKP-1 expression in ASM cells (Che et al., 2014a; Manetsch et al., 24 2012b; Quante et al., 2008) . Thus, it was of interest to examine the temporal kinetics of MKP-25 8 1 mRNA in this context. ASM cells were treated under the four experimental conditions as 1 outlined above and the temporal kinetics of MKP-1 mRNA expression measured. As shown in 2 Figure 2 , adding dexamethasone at 1 hr induced a significant 2.9±0.6-fold increase in MKP-1 3 mRNA expression at the 2 hr time point that was sustained for up to 24 hr (3.2±0.5-fold) 4 (P<0.05). Vehicle alone was without effect. When cells were stimulated with TNF, MKP-1 5 mRNA expression peaked at 1 hr and then declined; confirming the temporal kinetics of MKP-6 1 mRNA expression induced by TNF in this cell type . The impact of 7 treating cells with dexamethasone 1 hr after TNF stimulation was characterized by a sustained 8 expression of MKP-1 mRNA at 4-24 hr (P<0.05); that is, while TNF-induced MKP-1 mRNA 9 expression is transient, adding dexamethasone at 1 h ensures that MKP-1 mRNA expression 10 exists at the later time points. We were intrigued to examine the consequence of this sustained 11 expression of MKP-1 mRNA expression. 12 13 Treatment with dexamethasone 1 hr after TNF stimulation results in sustained MKP-1 14 protein upregulation: effects on p38 MAPK phosphorylation 15 MKP-1 is an immediate early gene that can be rapidly translated into protein (Sun et al., 1993) . 16
MKP-1 dephosphorylates members of the MAPK superfamily and in ASM cells we have 17
shown that the extent and duration of p38 MAPK phosphorylation is controlled by MKP-1 18 (Manetsch et al., 2012a; . Thus it is likely that MKP-1 mRNA expressed 19 as a result of adding dexamethasone after TNF stimulation may exert similar repressive effects, 20 although the impact of this regulatory network after the peak of cytokine expression has been 21 established was unknown. To address this, we compared the temporal kinetics of MKP- In Prabhala et al. we showed that IL-6 cytokine expression in ASM cells 18 is temporally controlled by regulatory network between MKP-1, p38 MAPK and TTP. By 19 controlling p38 MAPK phosphorylation, MKP-1 ensures that TTP mRNA and protein is 20 expressed and made functional in temporally-specific manner. Dexamethasone-induced MKP-21 1 will likely contribute in a similar, TTP-dependent way. To confirm this assertion, we 22 examined the impact of dexamethasone (at 1 hr) on the temporal kinetics of TTP mRNA 23 expression stimulated by TNF. As shown in Figure 4 , TNF increased TTP mRNA expression 24 in ASM cells with a peak at 1 hr. TTP is a p38 MAPK-responsive gene (Mahtani et al., 2001; 25 Prabhala et al., 2015) , accordingly, it is interesting to note that at 2 hr, the same time point 1 where dexamethasone treatment increases MKP-1 protein upregulation ( Figures 3B & 3C) , 2 mirrored by repressed p38 MAPK phosphorylation ( Figures 3B & 3D) , TTP mRNA expression 3 is significantly repressed (Figure 4: P<0.05 ). Vehicle and dexamethasone-only controls had no 4 significant effect on TTP mRNA expression (Figure 4) . 5 6 Treatment with dexamethasone 1 hr after TNF stimulation increases abundance of the 7 unphosphorylated (active form) of TTP, not TTP protein upregulation 8
Finally, we examined TTP protein upregulation and activity by Western blotting using the 9 rabbit antisera against TTP -Sak21. TTP protein stability and activity is controlled by 10 phosphorylation. TTP phospho-forms appear with different electrophoretic mobility on SDS-11 PAGE and can be detected by Sak21. When TTP is phosphorylated by MK2 the protein is 12 stabilized Hitti et al., 2006; Tchen et al., 2004) , but this phosphorylated 13 form of TTP is inactive as an anti-inflammatory RNA destabilizing factor (Marchese et al., 14 2010 ). In the unphosphorylated state, TTP is active and can induce mRNA decay however; this 15 form of TTP is also subject to degradation by the ubiquitin-proteasome system (Brook et al., 16 2006) . Previous studies utilizing Sak21 (King et al., 2009b; Mahtani et al., 2001; Prabhala et 17 al., 2015; Rahman et al., 2015) reported that bands at higher molecular weight indicate 18 phosphorylated TTP (inactive), while lower bands are unphosphorylated (active). Thus, it is 19 critical to note that it is not just the amount of TTP protein present that is important (because 20 this may be the inactive, but stable, phosphorylated form), but the activity (estimated by 21 densitometric analysis of unphosphorylated immunoreactive bands detected by Sak21). Figure 5B (TNF then dex at 1 hr)) and densitometric analysis; where Figure 5C is 1 total TTP protein upregulation (normalised to -tubulin) and Figure 5D is TTP (% active) (i.e. 2 % unphosphorylated TTP/total TTP) over time. TNF upregulates TTP protein in a temporally-3 distinct manner ( Figure 5C ) and interestingly, it appears that the total amount of TTP is reduced 4 by dexamethasone (albeit non-significantly); this aligns with the mRNA data. But it is the 5 activity, not the amount of TTP that dictates its anti-inflammatory function. Notably, at 1 hr 6 after TNF stimulation, TTP is observed in both phosphorylated and unphosphorylated 7 immunoreactive forms ( Figures 5A & 5B) . Densitometric analysis revealed that TTP (% active) 8 was 43.3±2.3% ( Figure 5D ); these data concur with our earlier study . 9
Notably, the impact of dexamethasone aligned with its ability to increase MKP-1 and repress 10 p38 MAPK phosphorylation at 2 hr; as shown in Figure 5B , there is a region of 11 immunoreactivity indicative of unphosphorylated phospho-forms at 2 hr. This is shown in 12 Figure 5D , where TTP (% active) was significantly greater in cells treated with dexamethasone 13 (41.0±2.4%), compared to TNF alone (24.9±5.4%) at the same time point (P<0.05). Taken 14 together our study suggests that by increasing MKP-1, dexamethasone represses p38 MAPK 15 to control TTP phosphorylation status (and therefore TTP activity) in a temporally-specific 16 manner to regulate IL-6 cytokine secretion in ASM cells. 17 has been shown to deactivate p38 MAPK and co-operate with TTP to orchestrate cytokine 5 expression. Our previous study in ASM cells showed that TTP acts in a 6 negative feedback manner to temporally regulate cytokine expression via MKP-1/p38 MAPK 7 dynamic control. Although corticosteroids have been shown to increase MKP-1 and deactivate 8
MAPKs in ASM cells (Issa et al., 2007; Quante et al., 2008) , a direct examination of the 9 expression and activity of TTP, and its regulation by dexamethasone-induced MKP-1 had not 10 been explored. 11
We address this herein and confirm that dexamethasone induces MKP-1 mRNA expression 12 and protein upregulation in ASM cells. We commonly pretreat ASM cells with corticosteroids 13 for 1 hr (Che et al., 2014b; Quante et al., 2008; Rahman et al., 2014) This is the first study to demonstrate that dexamethasone alone has no effect on TTP mRNA 21 expression and protein upregulation in ASM cells and indicates that cell type differences exist. 22
In A549 pulmonary epithelial cells, Smoak & Cidlowski (Smoak and Cidlowski, 2006) showed 23 that 100 nM dexamethasone induced TTP expression by 4-5-fold from 2-8 hr. This was 24 confirmed by King et al., where dexamethasone (albeit at 10-fold higher concentration, i.e. 1 25 µM) induced a 3-4-fold induction in TTP mRNA expression after 1 hr of treatment that was 1 sustained for up to 18 hr (King et al., 2009b) . Why differences exist in ASM cells is unclear at 2 present, although perhaps the relative expression of MKP-1 vs. TTP in each cell type may play 3 a compensatory role (Rahman and Ammit, unpublished data) . 4
Regardless of the relative expression of each of the players in this regulatory network, the 5 emerging view is that MKP-1/p38 and TTP co-operate in a coordinated fashion to orchestrate 6 cytokine expression. These molecules are amenable to manipulation and represent legitimate 7 targets for pharmacotherapeutic intervention. But perhaps most notably, our study has revealed 8 that the timing of the intervention is important. As outlined in our recent review (Prabhala and 9 Ammit, 2015) , TTP can be directly regulated by p38 MAPK in a number of ways, but as its 10 mRNA expression and protein stability is p38 MAPK-mediated, pretreatment with p38 MAPK 11 inhibitors would result in reduced expression of this critical anti-inflammatory protein. This is 12 not ideal. Instead, we have shown in the current study that by adding dexamethasone after 13 stimulation by TNF had commenced (therapeutic protocol), MKP-1 induction is allowed to 14 occur and protein is expressed at 2 hr. This then acts to reduce p38 MAPK phosphorylation 15 and consequently repress TTP mRNA expression at this time point. However, TTP is a highly 16 adaptable molecule that can exert anti-inflammatory power even at very low levels of 17 expression. This is because p38 MAPK also controls the switch between active and inactive 18 TTP phospho-forms. Put simply, the anti-inflammatory function of TTP is dictated by the 19 phosphorylation status of TTP at S52 and S178 (phosphorylated -OFF; unphosphorylated -20 ON) (Mahtani et al., 2001) . This is detected in our study as an increase in the TTP (% active) 21 at 2 hr. Also notable from our study is the predominance of the higher molecular weight, 22 immunoreactive band for TTP; this equates to the inactive phosphorylated form of TTP. By 23 confirming that TTP exerts anti-inflammatory activity when in the unphosphorylated form, our 24 14 results in ASM cells are in accord with recent publication that states "that TTP is most evident 1 when it is least active and most active when it is least evident" . 2 Collectively, our study suggests that corticosteroids increase TTP activity, not expression, via 3 MKP-1 in a p38 MAPK-mediated manner. Excitingly, as the phospho-states of TTP are 4 amenable to pharmacological manipulation, our study reveals a number of potential sites for 5 intervention and demonstrates that switching TTP on to repress cytokines in airway 6 inflammation is a feasible strategy towards combating respiratory disease. 
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